Literature DB >> 10858645

The topoisomerases of protozoan parasites.

S J Cheesman1.   

Abstract

Protozoan parasites are responsible for a wide range of debilitating and fatal diseases that are proving notoriously difficult to treat. Many of the standard chemotherapies in use today are expensive, have toxic side effects and, in some cases have marginal efficacy because of the emergence of drug-resistant parasites. In the search for more effective treatments, protozoan topoisomerases are now being considered as potential drug targets, building on the clinical success of anticancer and antibacterial agents that target human and bacterial topoisomerases. In this review, Sandra Cheesman explores progress in this relatively new but potentially important field of research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858645     DOI: 10.1016/s0169-4758(00)01697-5

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  13 in total

1.  Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.

Authors:  Jean-François Marquis; Isabelle Hardy; Martin Olivier
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 2.  DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.

Authors:  Carlos García-Estrada; Christopher Fernández Prada; Celia Fernández-Rubio; Francisco Rojo-Vázquez; Rafael Balaña-Fouce
Journal:  Proc Biol Sci       Date:  2010-03-03       Impact factor: 5.349

Review 3.  Targeting purine and pyrimidine metabolism in human apicomplexan parasites.

Authors:  John E Hyde
Journal:  Curr Drug Targets       Date:  2007-01       Impact factor: 3.465

4.  Antileishmanial Mechanism of Diamidines Involves Targeting Kinetoplasts.

Authors:  Gyongseon Yang; Gahee Choi; Joo Hwan No
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Topoisomerase II from Human Malaria Parasites: EXPRESSION, PURIFICATION, AND SELECTIVE INHIBITION.

Authors:  Devaraja G Mudeppa; Shiva Kumar; Sreekanth Kokkonda; John White; Pradipsinh K Rathod
Journal:  J Biol Chem       Date:  2015-06-08       Impact factor: 5.157

6.  Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum. A new potential target for anti-parasite drugs.

Authors:  Tobias Hanke; María J Ramiro; Sonia Trigueros; Joaquim Roca; Vicente Larraga
Journal:  Nucleic Acids Res       Date:  2003-08-15       Impact factor: 16.971

Review 7.  Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery.

Authors:  Rafael Balaña-Fouce; Raquel Alvarez-Velilla; Christopher Fernández-Prada; Carlos García-Estrada; Rosa M Reguera
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-08-24       Impact factor: 4.077

8.  Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum.

Authors:  César Ordóñez; Javier Alfonso; Rafael Balaña-Fouce; David Ordóñez
Journal:  J Biomed Biotechnol       Date:  2009-07-27

9.  Deletion study of DNA topoisomerase IB from Leishmania donovani: searching for a minimal functional heterodimer.

Authors:  Rosario Díaz González; Yolanda Pérez Pertejo; David Ordóñez; Rafael Balaña-Fouce; Rosa M Reguera
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

10.  Identification of Leishmania donovani Topoisomerase 1 inhibitors via intuitive scaffold hopping and bioisosteric modification of known Top 1 inhibitors.

Authors:  Rajinikanth Mamidala; Papiya Majumdar; Kunal Kumar Jha; Chandramohan Bathula; Rahul Agarwal; M Thirumala Chary; Hemanta K Majumder; Parthapratim Munshi; Subhabrata Sen
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.